Literature DB >> 9590128

Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride.

S Schwartz1, C Caceres, I De Torres, J Morote, J M Rodriguez-Vallejo, J Gonzalez, J Reventos.   

Abstract

We have analyzed the effects of the 5alpha-reductase inhibitor, finasteride (MK906), on the mRNA expression of the epidermal growth factor receptor and c-erbB-2 genes, in benign prostatic hyperplasia explant cultures treated with testosterone and with testosterone plus finasteride. A decrease of the epithelial cell content and an androgen-independent basal cell re-epithelialization was observed during the first 10 days of culture, suggesting a role of basal cells as stem cells involved in androgen-independent epithelial regeneration. Using a semi-quantitative reverse transcription polymerase chain reaction technique, we observed a significant decrease in expression of the epidermal growth factor receptor in the cultures treated with finasteride whereas no effect of finasteride on c-erbB-2 transcription was detected, although the expression of both genes was increased by dihydrotestosterone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590128     DOI: 10.1002/(sici)1097-0215(19980518)76:4<519::aid-ijc13>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.

Authors:  Magdalena M Grabowska; Brindar Sandhu; Mark L Day
Journal:  Cell Signal       Date:  2011-10-14       Impact factor: 4.315

Review 2.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.